Konstantinos Vazaios

Mr. Konstantinos Vazaios

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KVKonstantinos Vazaios
Konstantinos Vazaios
PLPatricia Hernández López
Patricia Hernández López
TATineke Aarts-Riemens
Tineke Aarts-Riemens
ADAnnet Daudeij
Annet Daudeij
Vera KempVera Kemp
Vera Kemp
JKJürgen Kuball
Jürgen Kuball
Due to the minimal survival benefits of existing therapies for pediatric diffuse midline glioma (DMG) patients, new therapeutic modalities are being investigated. Immunotherapies such as CAR-T cells and oncolytic viruses (OVs) are part of these efforts, as evidenced by the increasing number of clinical trials. αβ T cells engineered with a high-affinity γ9δ2 T-cell receptor (TEGs) are immune cells designed to target metabolic changes in malignant or virally infected cells via BTN2A1 and BTN3A. Because the expression of BTN2A1 and BTN3A can be altered in tumor and infected cells, combining TEGs and OVs could potentially enhance the anti-tumor response. We investigated this hypothesis in the following study. We demonstrate that TEGs can indeed target DMG, which expresses BTN2A1 and BTN3A at varying levels, and that OVs can further enhance the expression of BTN3A—but not BTN2A1—in DMG. Functionally, TEGs killed DMG cell cultures, and this killing was further increased after OV infection of the DMGs with either adenovirus Δ24-RGD or reovirus R124 under suboptimal conditions. However, this additive effect was lost when γ9δ2 TCR–ligand interaction was boosted by pamidronate. This study demonstrates the additive effect of combining OVs and Vγ9Vδ2 TCR-engineered immune cells under suboptimal conditions and supports a combination strategy to enhance the efficacy of both therapeutic modalities.

15 April 2024 in Molecular Therapy Oncology
Verified
Journal Article
Open access
KVKonstantinos Vazaios
Konstantinos Vazaios
ΕSΕftychia Stavrakaki
Εftychia Stavrakaki
LVLisette B. Vogelezang
Lisette B. Vogelezang
JJJie Ju
Jie Ju
PWPiotr Waranecki
Piotr Waranecki
Martine LamfersMartine Lamfers
Martine Lamfers
Despite decades of research, the prognosis of high-grade pediatric brain tumors (PBTs) remains dismal; however, recent cases of favorable clinical responses were documented in clinical trials using oncolytic viruses (OVs). In the current study, we employed four different species of OVs: adenovirus Delta24-RGD, herpes simplex virus rQNestin34.5v1, reovirus R124, and the non-virulent Newcastle disease virus rNDV-F0-GFP against three entities of PBTs (high-grade gliomas, atypical teratoid/rhabdoid tumors, and ependymomas) to determine their in vitro efficacy. These four OVs were screened on 14 patient-derived PBT cell cultures and the degree of oncolysis was assessed using an ATP-based assay. Subsequently, the observed viral efficacies were correlated to whole transcriptome data and Gene Ontology analysis was performed. Although no significant tumor type-specific OV efficacy was observed, the analysis revealed the intrinsic biological processes that associated with OV efficacy. The predictive power of the identified expression profiles was further validated in vitro by screening additional PBTs. In summary, our results demonstrate OV susceptibility of multiple patient-derived PBT entities and the ability to predict in vitro responses to OVs using unique expression profiles. Such profiles may hold promise for future OV preselection with effective oncolytic potency in a specific tumor, therewith potentially improving OV responses.

Verified
Journal Article
Open access
PDF file
KVKonstantinos Vazaios
Konstantinos Vazaios
RBRonja van Berkum
Ronja van Berkum
FCFriso Calkoen
Friso Calkoen
JLJasper van der Lugt
Jasper van der Lugt
Esther HullemanEsther Hulleman
Esther Hulleman
Oncolytic viruses (OVs) are characterised by their preference for infecting and replicating in tumour cells either naturally or after genetic modification, resulting in oncolysis. Furthermore, OVs can elicit both local and systemic anticancer immune responses while specifically infecting and lysing tumour cells. These characteristics render them a promising therapeutic approach for paediatric brain tumours (PBTs). PBTs are frequently marked by a cold tumour immune microenvironment (TIME), which suppresses immunotherapies. Recent preclinical and clinical studies have demonstrated the capability of OVs to induce a proinflammatory immune response, thereby modifying the TIME. In-depth insights into the effect of OVs on different cell types in the TIME may therefore provide a compelling basis for using OVs in combination with other immunotherapy modalities. However, certain limitations persist in our understanding of oncolytic viruses’ ability to regulate the TIME to enhance anti-tumour activity. These limitations primarily stem from the translational limitations of model systems, the difficulties associated with tracking reliable markers of efficacy throughout the course of treatment and the role of pre-existing viral immunity. In this review, we describe the different alterations observed in the TIME in PBTs due to OV treatment, combination therapies of OVs with different immunotherapies and the hurdles limiting the development of effective OV therapies while suggesting future directions based on existing evidence.

25 November 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ATAntonio Carlos Tallon-Cobos
Antonio Carlos Tallon-Cobos
KVKonstantinos Vazaios
Konstantinos Vazaios
PWPiotr Waranecki
Piotr Waranecki
MHMarliek van Hoesel
Marliek van Hoesel
ACAnnelisa M. Cornel
Annelisa M. Cornel
Esther HullemanEsther Hulleman
Esther Hulleman
Aggressive pediatric brain tumor models of ependymoma are highly sensitive to GD2-directed (CAR T) cell therapy

31 March 2026 in Molecular Therapy Oncology
Verified
Journal Article
Open access
KVKonstantinos Vazaios
Konstantinos Vazaios
ATAntonio C. Tallon-Cobos
Antonio C. Tallon-Cobos
LOLouisa P.J. van Oosterhout
Louisa P.J. van Oosterhout
PWPiotr Waranecki
Piotr Waranecki
ACAnnelisa M. Cornel
Annelisa M. Cornel
EHEsther Hulleman
Esther Hulleman
Despite the success of CAR (chimeric antigen receptor) T cells in hematological malignancies, their effectiveness against solid or brain tumors, such as pediatric diffuse midline gliomas (DMGs), is limited. CAR T cell success is hampered by factors including immunosuppression from DMGs and their surrounding tumor microenvironment (TME). Oncolytic viruses (OVs) can reverse this immunosuppression, suggesting a potential combination with CAR T cells. Here, we show that infection with Goravir adenovirus and R124 reovirus induced DMG cell lysis (n = 6 cultures), with minimal effect on the viability of B7H3- or GD2-targeted CAR T cells, even at high virus concentrations. In addition, RNA sequencing of infected tumor cells revealed altered gene expression in cell cycle and antiviral response pathways. Furthermore, co-cultures of CAR T cells with OV-infected DMGs enhanced CAR T-specific anti-tumor killing in 14 out of 24 cases. The successful combinations exhibited enhanced cytokine and chemokine release, coupled with an increased cytotoxic phenotype. These findings highlight the benefit of DMG pre-infection with OVs to boost CAR T cell activity and suggest that immune stimulation is a key driver of enhanced combination responses.